Clarity Pharmaceuticals has three lead products, SAR-bisPSMA, SAR-Bombesin, and SARTATE. The lead drugs are currently progressing through eight clinical trials, including three theranostic trials ...

Meanwhile, the company's three lead products SAR-bisPSMA, SAR-Bombesin and SARTATE are actively progressing through eight clinical trials, comprising three theranostic trials and five diagnostic ...

Further preclinical and translational studies evaluating the potential therapeutic effects of GRPR ligands are warranted. All mammalian bombesin receptors (GRPR, NMBR, and the orphan receptor BRS-3 or ...